Physician profile
James S Lee
NPI 1720223803
$3,315.04
in general payments reported to CMS, 2019-2025
30 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $319 · 2021: $480 · 2022: $304 · 2023: $294 · 2024: $533 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $523.96 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $490.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.61 | 2019-2025 | Farxiga |
| Medtronic, INC. | $202.62 | 2022-2025 | Corevalve Evolut R, Mycarelink |
| Baxter Healthcare | $200.81 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $197.57 | 2019-2023 | Xarelto |
| Pfizer INC. | $177.54 | 2019-2025 | |
| Amarin Pharma, INC. | $174.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $127.55 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.23 | 2019-2023 | Lifevest |
| Inspire Medical Systems, INC. | $121.80 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.88 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $82.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $63.86 | 2020-2024 | Camzyos |
| Boston Scientific Corporation | $61.11 | 2019-2025 | Bodyguardian |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $46.11 | 2020-2023 | Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $45.37 | 2020-2024 | Opsumit |
| Sanofi-Aventis U.S. LLC | $42.96 | 2019 | |
| Amryt Pharma Holdings LTD | $42.96 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $34.13 | 2025 | Amvuttra |
| Welch Allyn | $33.57 | 2021 | |
| Atricure, INC. | $33.25 | 2022-2024 | |
| Bardy Diagnostics, INC. | $31.62 | 2019-2021 | |
| Esperion Therapeutics, INC. | $28.67 | 2021 | |
| Medtronic Vascular, INC. | $27.05 | 2019 | |
| Elutia, INC. | $24.39 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.92 | 2022 | |
| Abbott Laboratories | $20.29 | 2024 | Mitraclip |
| Philips North America LLC | $20.20 | 2022 | |
| Edwards Lifesciences Corporation | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.